Book / livre en 2 langues français and English

English links:

Finally we did My Book publication in English:

Marc The Invicible: A true story of my son’s resurrection from cardiac arrest followed by anoxic brain damage

SERIGNY SVETLANA , LUQUET JULIE , RICHARDSON ANNETTE

Kindle format:

https://www.amazon.com/Marc-Invicible-resurrection-cardiac-followed-ebook/dp/B088QQQKSZ

Paper book:

https://www.amazon.com/dp/B088T26YXB

Français:

Voilà mon livre : en 2 possible versions « Marc L’invincible » ( en français)

Kindle:

https://www.amazon.fr/dp/B07Y34WPXQ

en livre broché sur Amazon:

https://www.amazon.fr/dp/B07Y4KC5S1

Hla matched cord blood CP and ASD children’s clinical trails in Russia

Hère 2 clinical trails ( they are taking international patients but on payment basis you can ask)

Hère links on official trails on clinical trails.gov:

( with allogenic cord blood)

Cp

https://clinicaltrials.gov/ct2/show/NCT04098029

And ASD:

https://clinicaltrials.gov/ct2/show/NCT04099381

Hère new instructions for mails:

( at the stage you get person number you need to send NEW mail with number given) ! I did mistake to answer previous mail don’t repeat my mistakes 😉

So here instruction ver explicit : ( read well all points)

NSTRUCTIONS FOR TRANSFER OF INFORMATION BY EMAIL FOR CLINICAL TESTS

Email ct@cordbank.ru is designed for patients participating or planning to participate in clinical trials at the Dynasty Medical Center.

Sending messages to this e-mail indicates that you agree to the transmission of data, medical and other personal information via an open (unprotected by special means) communication channel.

Email is set up to help the researcher sort the letters and respond to them in a timely manner. When contacting the email address ct@cordbank.ru must follow the next rules, in case of the rules are not met, the researcher does not guarantee a response to the letter.

Incoming emails are processed in English and Russian, dates are displayed in DD / MM / YYYY format:

1. PRIMARY REQUEST FOR CLINICAL TESTS.

For the initial request for clinical trials, a letter should be sent to the researcher with the following heading:

PRIMARY _ CT _ REQUEST _ XX ,

Where XX indicate the clinical trial option: CP for cerebral palsy, AU – for autism;

Inside the letter you must provide the following information on the form:

Additionally, we request (this will help us to quickly determine the possibility of treatment) the most complete information about: is current medical condition of the patient, a brief description any held treatment and its effectiveness.

Further correspondence is conducted by replying to the previous letter so that the history of the correspondence is not interrupted. Please do not manually change the message header, do not send repeated requests and do not send new emails with attachments. If you are included in the study, you will be given a number with which you will continue to correspond with the researcher (see point 2).

2. FOR PATIENTS AT THE FIRST STAGE OF CLINICAL STUDY (SELECTION)

Patients included in the first stage of the study (selection) receive from the researcher an individual number that will need to be reflected in the title. Please make a NEW email with a NEW header. The new header will automatically sort your letters in the working group. Please write the first letter after entering the first stage of a clinical trial according to the following pattern:

CT_XX_S1 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher.

Patients can ask questions; send the requested documents (pdf, jpeg) at any time. Further correspondence is conducted by replying to the previous letter so that the history of the correspondence is not interrupted. Please do not manually change the message header, do not send repeated requests and do not send new emails with attachments.

Name of the patient

Date of Birth

Diagnosis

dates of diagnosis

Patient weight

Level GMFCS or ATEC

3. FOR PATIENTS ON THE SECOND AND THE THIRD STAGE OF A CLINICAL RESEARCH (SELECTION OF A GROUP AND PROCEDURE FOR THE INTRODUCTION OF CELLS).

After you have been assigned to the first or second study groups, and later, throughout the duration of the procedures, you can communicate with the researcher at any time on the topic of the clinical study. In order for you to receive prompt responses, you should change the subject of the heading in the following pattern:

CT _ XX _ S 2-3 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher in the second stage.

4. AFTER CONDUCTING THE INTRODUCTION OF CELLS.

After the first infusion of cells, the second infusion and until the end of the study, patients should transmit information about the effectiveness of treatment, for this, it is necessary to arrange the letter header as follows:

CT _ XX _ S 4 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher in the second stage.

All subsequent letters with research results should be sent in response to the first letter, without changing the title. Any questions or events about undesirable reactions should be sent to the researcher with such a title.

Инструкция по передачи информации по электронной почте для клинических испытаний. V003.02072019

Hla matched cord blood CP and ASD children’s clinical trails in Russia

Hère 2 clinical trails ( they are taking international patients but on payment basis you can ask)

Hère links on official trails on clinical trails.gov:

( with allogenic cord blood)

Cp

https://clinicaltrials.gov/ct2/show/NCT04098029

And ASD:

https://clinicaltrials.gov/ct2/show/NCT04099381

Hère new instructions for mails:

( at the stage you get person number you need to send NEW mail with number given) ! I did mistake to answer previous mail don’t repeat my mistakes 😉

So here instruction ver explicit : ( read well all points)

NSTRUCTIONS FOR TRANSFER OF INFORMATION BY EMAIL FOR CLINICAL TESTS

Email ct@cordbank.ru is designed for patients participating or planning to participate in clinical trials at the Dynasty Medical Center.

Sending messages to this e-mail indicates that you agree to the transmission of data, medical and other personal information via an open (unprotected by special means) communication channel.

Email is set up to help the researcher sort the letters and respond to them in a timely manner. When contacting the email address ct@cordbank.ru must follow the next rules, in case of the rules are not met, the researcher does not guarantee a response to the letter.

Incoming emails are processed in English and Russian, dates are displayed in DD / MM / YYYY format:

1. PRIMARY REQUEST FOR CLINICAL TESTS.

For the initial request for clinical trials, a letter should be sent to the researcher with the following heading:

PRIMARY _ CT _ REQUEST _ XX ,

Where XX indicate the clinical trial option: CP for cerebral palsy, AU – for autism;

Inside the letter you must provide the following information on the form:

Additionally, we request (this will help us to quickly determine the possibility of treatment) the most complete information about: is current medical condition of the patient, a brief description any held treatment and its effectiveness.

Further correspondence is conducted by replying to the previous letter so that the history of the correspondence is not interrupted. Please do not manually change the message header, do not send repeated requests and do not send new emails with attachments. If you are included in the study, you will be given a number with which you will continue to correspond with the researcher (see point 2).

2. FOR PATIENTS AT THE FIRST STAGE OF CLINICAL STUDY (SELECTION)

Patients included in the first stage of the study (selection) receive from the researcher an individual number that will need to be reflected in the title. Please make a NEW email with a NEW header. The new header will automatically sort your letters in the working group. Please write the first letter after entering the first stage of a clinical trial according to the following pattern:

CT_XX_S1 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher.

Patients can ask questions; send the requested documents (pdf, jpeg) at any time. Further correspondence is conducted by replying to the previous letter so that the history of the correspondence is not interrupted. Please do not manually change the message header, do not send repeated requests and do not send new emails with attachments.

Name of the patient

Date of Birth

Diagnosis

dates of diagnosis

Patient weight

Level GMFCS or ATEC

3. FOR PATIENTS ON THE SECOND AND THE THIRD STAGE OF A CLINICAL RESEARCH (SELECTION OF A GROUP AND PROCEDURE FOR THE INTRODUCTION OF CELLS).

After you have been assigned to the first or second study groups, and later, throughout the duration of the procedures, you can communicate with the researcher at any time on the topic of the clinical study. In order for you to receive prompt responses, you should change the subject of the heading in the following pattern:

CT _ XX _ S 2-3 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher in the second stage.

4. AFTER CONDUCTING THE INTRODUCTION OF CELLS.

After the first infusion of cells, the second infusion and until the end of the study, patients should transmit information about the effectiveness of treatment, for this, it is necessary to arrange the letter header as follows:

CT _ XX _ S 4 NNN,

Where XX – clinical trial option: CP for cerebral palsy, AU – for autism; NNN – a unique individual

number assigned to you by the researcher in the second stage.

All subsequent letters with research results should be sent in response to the first letter, without changing the title. Any questions or events about undesirable reactions should be sent to the researcher with such a title.

Инструкция по передачи информации по электронной почте для клинических испытаний. V003.02072019

Neuralink what do you think?

Neuralink what do you think?

I am sorry I am brain injured child mum so i am scepical and veru critical… ok? So this is just my thoughts about Neuralink presentation:

1)Cortical only level for naw ( they don’t go yet deeper)?

2)Elon Musk Neuralink haw much he gains 2020?

3) I am sorry that I am so critical but I am firsthand want to see proofs that it’s works ? To put in head of healthy pigs don’t prove anything to me ?

Not into paralyzed pigs ?!

4) Honestly he was talking about deep brain stimulation ( at the beginning) I personally know 3 children’s – the inventor of DBS is french neurochirurgien -as I was told – (professeur Philippe COUBES ? )I met him – so in 3 children’s I know which had sdb by him – it’s in fact don’t work 2-3 years – after still searching level of stimulation neded ….

I don’t know even one person for whom it’s works DBS? there’s re a lot published studies and they are sayin it’s works…where they 150000 persons for who un it worked I am searching them for 2 years! ? Any testimonials?

https://web.wpi.edu/Pubs/E-project/Available/E-project-081916-141158/unrestricted/8-19-16__DBS_IQP_Report,_Final.pdf

So…

5) What they are going to do with atrophy of mussels and with bones deformities?

Honestly? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989853/

they are giving technical briefings to bring in the best talent to bring this device to every person who needs it (great, but of course CEO Elon made $ 30,000 billion this year)?

Our brain is like an electrical network, and when it is damaged, it emits weak signals (but can electronics be compared to biology?) Neural communication amplifies weak signals (and much more in terms of reading and writing to the brain) and in the distant future will the tertiary level of the brain’s AI to do what the neural connection cannot do. Is this the largest technological and medical development since the 1800s. ????? I am not sure about this ….

Have they already got FDA approval for a breakthrough device? Is it money or real progress? An artificially implanted chip? I have a lot of questions and I am very careful about this …

https://youtu.be/DVvmgjBL74w

So what is all this ?

All this is PR and money making? Better to promise to send people to Mars. It is normal to collect money from dreamers, but not from the sick.

Yes. Work is underway on impulse-controlled prostheses. And if you manage to decorate the signals, then you can mentally control some auxiliary devices. It is a well-known misconception that we can surpass our creator. It is enough to look at the medieval paintings of how they tried to make a man with the help of springs and gears.

They do not yet know how to translate the chemistry of the brain and thinking into a conscious binary code. While they can train a person to strain something and relax something simple. For example, take a glass of prostheses controlled by a brain impulse.

So it’s gives realistic perspective….

Also : « « Former employees told Stat News that the company was chaotic, and that researchers were under intense pressure to rush through projects. Scientists were sometimes given weeks to complete projects that should take months, for example. “They are building a medical device and a surgical approach to implant that medical device, and they’re approaching it with the use of a tech company — move fast and break things,” one employee said. »

What could go wrong ah?

https://www.theverge.com/2020/8/28/21406143/elon-musk-neuralink-ai-pigs-demo-brain-computer-interface

« The announcement of the technology was based on two white papers published in bioRxiv, reports written by NeuraLink scientists and not peer-reviewed. In both published white papers, no attempt has been made to use the recorded neuronal data for the purposes of a BCI, and no attempts to simulate neurons through NeuraLink have been reported.

It’s fairly likely the company has achieved more than is reported in the white papers, the nature of scientific research being that breakthroughs are sometimes made years before they can be published. »

« Neuralink’s microscopically slender electrodes are designed to provide longer-term recording than current electrodes and produce less tissue damage, but it’s still not clear how this will stand up over time. In the first study cited, recordings were made from one rat implanted with the electrodes for 60 days, with the implants falling off prematurely in the other three rats studied.

By comparison, the Utah array has reported longevity of six to nine years when implanted into a primate brain. »

You see I eventually don’t use any my own words ….

https://www.medicaldevice-network.com/features/neuralink-fact-fiction/

And this one : https://www.bbc.com/news/technology-53987919

The live chat 31 July about the clinical trials, future research, and treatments with cord blood in Russia

Link to lisen interview

https://www.facebook.com/AutismResearchCoalition/videos/367686797553262/

Dr. Olga Tyumina is the President of Ruscord, a non-profit organization of specialists and organizations in the field of procurement, storage and use of umbilical cord blood and cellular technologies. Dr. Tyumina is a prominent doctor in medical sciences, professor of the Russian Academy of Sciences, honored health worker in the Samara Region (Russia), and the Director of the Samara Regional Medical Center, Dynasty. She is the author of 120 publications and holds multiple patents, registered computer programs and monographs.

Dr. Stanislav Volchkov is the Deputy Director of the Samara Regional Medical Center, Dynasty, the Executive Director of the non-profit Hematopoietic Progenitor Cells Registry, Expert of the Fund for Assistance to Small Innovative Enterprises in Science and Technology, Founder of the Institute of Biotechnology and Pharmacology Inbiopharma, LLC, and is a certified designee for biomedical cellular products acquired by Ministry of Health of the Russian Federation.

In this live chat we will discuss the clinical trials, future research, and treatments currently provided at the Center of Cellular Technologies in Samara (Russia) using donor cord-blood transfusions and other stem cell therapies for the treatment of Autism, Cerebral Palsy and other developmental disorders.

Galileo et Alinker

Galileo : Galileo | Side Alternating Vibration

Dernière étude 2019: The immediate influence of various whole-body vibration frequency on balance and walking ability in children with cerebral palsy: a pilot study:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732549/

Worth Knowing – Kids

Autres études ( il y a beaucoup)

« Le WBVT fourni par Galileo plate est caractérisé par des mouvements de bascule qui stimulent un modèle de mouvement similaire à la démarche humaine. Celles-ci entraînent l’activation de circuits vertébraux propriétaires-réceptifs, conduisant ainsi à des contractions musculaires rythmiques compensatoires dans les membres inférieurs et le tronc. Nos participants ont non seulement affiché des améliorations de la masse musculaire, mais également des améliorations de la teneur en minéraux osseux et de la densité allant de 1 à 5%. L’augmentation de la masse osseuse était probablement due à l’effet de l’action musculaire sur l’os pendant le WBVT, combiné aux effets de l’amélioration de la mobilité observée. Ainsi, nos résultats cadrent bien avec la théorie du mécanostat, dans laquelle la charge mécanique (dans ce cas, les contractions musculaires générées par la plate-forme de vibration et l’amélioration de la mobilité) a entraîné des effets positifs sur les os, tels qu’une augmentation de la masse osseuse. Notez que nos résultats étaient similaires à ceux observés par Stark et al. après 6 mois de thérapie combinée dans un groupe de 78 enfants atteints de GMFCS I à V, qui ont rapporté respectivement une augmentation de 2,3% et 5,7% de la densité et de la teneur totale en minéraux osseux. Cependant, leur intervention impliquait non seulement le WBVT, mais aussi d’autres formes de physiothérapie, de musculation et d’entraînement sur tapis roulant, ce qui rendait impossible l’identification des effets spécifiques du WBVT. Néanmoins, Wren et al. ont examiné l’impact de l’entraînement quotidien aux vibrations seul sur la santé osseuse des enfants atteints de PC âgés de 6 à 12 ans, observant des améliorations de la zone osseuse corticale par rapport à un régime de simplement se tenir debout sur le sol8.

https://www.nature.com/articles/srep22518.pdf

https://www.nature.com/articles/srep22518

Alinker: ( vélo – debout) pour marcher ( Marc manque encore 2 cm longueur des jambes)

Duke study for ASD children’s with allogenic and autologous cord blood

Interview : by Enrique Basurto :

Link to lisen: https://www.facebook.com/AutismResearchCoalition/videos/2830606040559221/

Key takeaways from our live interview with Dr. Joanne Kurtzberg today re. the results of the phase-II trial using cord-blood infusions in children with Autism,

1. As noted in the Discussion section of the publication, the research Team believes that the lower than needed sample of children with non-verbal IQ > 70 might have compromised the results of the study. However, although the study did not meet the target outcome (as measured by the Vineland socialization scale), there were statistically significant improvements in the higher non-verbal IQ (NVIQ) cohorts particularly in 4-to-7 y.o. in communication scales, eye tracking and EEG

2. Currently, there are 3 stem cell studies for Autism where the Duke Team is involved: a) Using cord tissue MSCs (where 500-1,000 doses could be extracted from a single cord and therefore multiple infusions could be received) with 4-to-7 year olds with NVIQ > 70 (with NVIQ measured at Duke as opposed to remotely in order to -hopefully- ensure statistical significance next time). b) A study in China aiming at diagnosing and treating Autism using cord-tissue infusions earlier in life. c) A small trial with ASD adults ages 18 to 35. These 3 trials are already funded but currently on hold due to COVID-19 but are expected to resume ASAP. Dr. Kurtzberg noted that in the future, it is possible that a combination of multiple stem cell sources could show higher efficacy than any individual source could achieve on its own, e.g. starting with a cord-blood infusion followed by cord-tissue MSCs infusions every 3-6 months to sustain benefits

3. In order to get FDA-approval for cord-blood infusions in the US, it is necessary to show definite benefit in a phase-III randomized placebo controlled trial. To that effect, the Duke Team believes that the results from the phase-II trial are compelling enough to seek funding for a phase-III trial with cord blood infusions in 4-to-7 year olds with NVIQ > 70. (As a side note, limiting the sample to 4-7 y.o. with NVIQ > 70 does not mean that lower functioning children could not benefit from cord-blood infusions, that is simply to delineate the inclusion criteria that is most likely to demonstrate benefits in the shortest amount of time)

4. During the course of the phase-II trial, the vast majority of parents who « guessed » when their children had received the cord-blood infusion (as opposed to the placebo) based on the improvements they observed in behaviors, focus, concentration, socialization, testing and communication (by ether increasing their vocabulary or by appropriately using the words they had) were correct. OTOH, The placebo effect was reportedly higher than expected, part of the reason why this could have happened was due to the tools used to assess improvements in 2-to-4 year olds, specially given the fact that this is an age where children in general could potentially acquire various skills

5. In principle, it is possible to get FDA-approval for an expanded access program using donor cord-blood infusions for children with Autism. However, the waiting list for the autologous infusions already surpasses the capacity of the Team at Duke. That said, Duke is currently working with a few other clinics/centers/hospitals to open up expanded access programs around the US (e.g. MD Anderson, Rutgers, etc.) that can provide access to cord-blood infusions without the long waiting lists

6. Although MSCs can be manufactured from adipose tissue or from the bone marrow, based on several studies, Dr. Kurtzberg believes MSCs from umbilical cord tissue are more potent. That said, studies using MSCs using bone marrow have also shown positive outcomes in Autism. Dr. Kurtzberg mentioned exosomes are controversial and have not been studied as much as MSCs. MSCs activate macrophages so the use of exosomes without MSCs may not cause the kind of benefits compared to when MSCs are present

7. Regarding prep work, the research Team has not found any indication that diets, supplements or other biomedical treatments can increase that chance of success from stem cell therapy

8. In theory, infusing HLA-matched (or partially HLA-matched) cord-blood in a recipient should increase the amount of time that the donor cells can survive in the recipient’s body. Also, by infusing HLA-matched cord blood there is less chance of « sensitizing » the recipient’s system against foreign HLA which could potentially make the recipient develop antibodies that could limit the donor base later in life if transfusions were needed for other reasons

Publication -> https://autismresearchcoalition.files.wordpress.com/2020/07/0-1.pdf

#AutismIsMedical #AutismIsTreatable #1in54 #FlattenTheAutismCurve #AutismPandemic #TheRealPandemic

« In a subanalysis of children without intellectual disability (ID), allogeneic, but not autologous, CB was associated with improvement in a larger percentage of children on the clinician-rated Clinical Global Impression-Improvement scale”

And: “Children without ID treated with CB showed significant improvements in communication skills (VABS-3 Communication Domain), and exploratory measures including attention to toys and sustained attention (eye-tracking) and increased alpha and beta electroencephalographic power.”

“The rationale is that CB CD14+ monocytes act through paracrine signaling to modulate brain inflammation and/or immune abnormalities, improving brain function and behavior.”

“One hundred eighty children, aged 2-7 years (mean ± SD, 5.47 ± 1.65) who met DSM-5 criteria for ASD participated. Diagnosis was based on the Autism Diagnostic Observation Schedule-217 and Autism Diagnostic Interview, Revised.18 Participants were screened for a genetic cause of ASD with testing for Fragile X and chromosomal microarray. Inclusion criteria included (1) negative genetic testing, (2) qualified CB unit with a minimum banked total nucleated cell dose of ≥2.5 × 107 cells/kg or ≥4/6 HLA-matched allogeneic unrelated CB unit, (3) stable on medications for ≥2 months, (4) ability to travel to study site twice, (5) English speaking, and (6) normal absolute lymphocyte count (≥1500/μL).”

But : “Infused dose was not associated with the primary and secondary outcomes, with the exception of the CGI. The allogeneic cohort received a higher TNC dose compared with the autologous cohort (3.8 × 107/kg vs 2.7 × 107/kg) making it impossible to determine whether the effect in the allogeneic group was due to the higher cell dose or to CB type.”

“When participants with NVIQ ≥70 were analyzed separately, the results indicated that participants without ID who were treated with CB exhibited significantly increased relative alpha powerposterior/toys (P = .02) and significantly increased relative beta1 powerall brain regions/social (P = .02) compared with the placebo group (Figure 5). No main effects were found for theta or gamma power.”

“However, for children without ID, clinician CGI ratings indicated that children treated with allogeneic CB, but not those treated with autologous CB, showed improvement over placebo. Children without ID also showed significantly greater improvement in a prespecified secondary outcome measure of VABS Communication SS when treated with CB compared with placebo.”

https://www.jpeds.com/article/S0022-3476(20)30334-6/pdf

EXO serum or haw I found best cream for me while studying cord blood ….

Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulates rejuvenation of human skin!!!!

https://www.researchgate.net/publication/319867439_Exosomes_derived_from_human_umbilical_cord_blood_mesenchymal_stem_cells_stimulates_rejuvenation_of_human_skin

And : https://www.researchgate.net/publication/322179874_Exosomes_from_human_umbilical_cord_blood_accelerate_cutaneous_wound_healing_through_miR-21-3p-mediated_promotion_of_angiogenesis_and_fibroblast_function/fulltext/5a4ad7b4aca272d29464762d/322179874_Exosomes_from_human_umbilical_cord_blood_accelerate_cutaneous_wound_healing_through_miR-21-3p-mediated_promotion_of_angiogenesis_and_fibroblast_function.pdf?origin=publication_detail

Denise Serigny my mother in law send me her testimonial for EXO: (she does not have Facebook now) and she is 78 years old!

But this is her experience after 6 months:

“What a pleasure to put on my face, morning and evening, this little drop of EXO.

Immediately i felt my skin becomes “full” of this elixir and in a few seconds nourishes and beautifies it.

I always thought, that i will become “old » in natural way… I would never resort to cosmetic surgery, I want to keep on my face the traces of my history.

EXO, suits me fully : gradually reducing fine wrinkles and slightly filling the skin , giving it a « healthy glow » effect.”

Description EXO :

https://lookaside.fbsbx.com/file/%D0%9E%D0%BF%D0%B8%D1%81%D0%B0%D0%BD%D0%B8%D0%B5%20EXO%20Serum%20EN.docx?token=AWy2Sz8l3W6w561lS1nsuoXDsydkHlabdndHPLlA82ufjp-06XiLoelL9vyUark5zQpa9w5S9HEDshJNivzo5ztEvnLzj-6WIUynR2GFxGv74c6Dmte9WfcytegvGmw–OoUmNIMMub0aAzZp2pYPue05NQsdrU0cEdHQfuBPzHTspduQb5KtCVEefB6OOPLoMtKEE8kXRMaLt3NtgjreeZe

A lot of friends ask me how to maintain youth and look good at my age (I’m 46 on the left of photo) …so ….honestly, I think several factors play a role …

Of course genetics; nutrition and physical activity … but for the skin …. not only …. my friends often ask me what cream I use …. I honestly did not use any;) before….but recently we drove to treat our son brain injury in Samara and there I found a cream on a natural basis – based on exosomes ….from umbilical cord blood .. (I studed a lot of scientific literature on umbilical cord blood as you can find in previous articles on my blog….for my son and therefore I know a lot about its capabilities) therefore it was this serum with exosomes that I personally was interested to give a try and honestly the result on my face became already visible after 2 months!

I can testify that after 8 months of treatment an excellent result on my face skin really great some wrinkles are less visible (but the result is absolutely natural) not like the stretched and inflated faces of Botox stars …oh … the horror … 😂

I am 46 years old, and I am very pleased with EXO serum, it is effective, soft and natural – and, in my opinion, it is ideal (I am not a supporter of Botulique toxins and not a supporter of plastic surgeries – I consider this exagération – in pursuit of “rejuvenation” and results …. haw to say – better to use in horror films- very unnatural and doubtful …. and it could harm your health ! Botox can harm you it’s toxic…..

Of cause at the same time, as any woman I’m looking for a way to stay attractive – but as “natural” as possible and therefore I personally really like EXO Serum.

It should be noted that this is not just external beauty, but also real skin health and restoration of skin functions! So very very healthy !!!!

Exosomes of umbilical cord mesenchymal cells have proven effective for skin rejuvenation in preclinical studies by a group of scientists from the USA and China. Experiments have shown that exosomes can potentially be used to regenerate and rejuvenate the skin with various defects. The work was published in ACS Omega magazine:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941387/

Exosomes have the ability to stimulate the proliferation of dermal fibroblasts, as well as enhance their production of collagen, elastin and fibronectin.

As I wrote earlier, EXO underwent research in Samara for burns and healing wounds.

Everything was perfectly explained long ago in the video: https://drive.google.com/file/d/1tICdE9m3KvrVelrWjTkXQeRta2NuKICL/view

I buy my face EXO serum in Russia! I live in france but I prefer this serum than any other big French marks of face creams and serums….

Here: Exo-store.ru

You want to see files find more videos and about see on fb page:

https://www.facebook.com/groups/537120110469531/?ref=share

So Israël will start randomized HBOT trail for COVID19 ?

So here study in Israel will start soon:

https://clinicaltrials.gov/ct2/show/NCT04358926

The purpose of Israel’s study is to evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner.

This Swiss study and also some studies in USA ( with hbot) still makes me think that hbot may be good therapie for COVID19 patients :

I will explain 

Hère Swiss last study: ( published in Lancet)

This is new interesting study:

« The endothelial tissue of younger patients is usually capable of coping well with the attacks launched by the virus. The situation is different for patients suffering from hypertension, diabetes, heart failure or coronary heart diseases, all of which have one thing in common – their endothelial function is markedly impaired. If patients such as these become infected with SARS-COV-2, they will be particularly at risk, as their already weakened endothelial function will diminish even further, especially during the phase in which the virus reproduces the most.  « 

Study:

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30937-5/fulltext

Link to Swiss article :

http://www.en.usz.ch/media/press-releases/pages/covid-19-endotheliitis.aspx?DeviceChannel=Mobile

So in fact they talk about :

Endothelial dysfunction  And capacity to produce nitric oxide (NO)….

And we have a lot of studies ( with hbot) One of them Shai study:

« In a study on rats with normal mitochondrial function, HBOT increased the production of adenosine triphosphate in muscle tissue compared to a control group [29]. Moreover, in a clinical study by Li et al., it was demonstrated that HBOT may improve myocardial blood perfusion, reduce inflammation and vascular endothelial dysfunction, and further improve myocardial microcirculation in patients after the implantation of drug-eluting stents [30]. Aparci et al. evaluated the changes following a series of 10 hyperbaric sessions in diabetic patients [31] »

https://www.researchgate.net/publication/338667041_The_effect_of_hyperbaric_oxygenation_therapy_on_myocardial_function

So if  HBOT improve myocardial blood perfusion, reduce inflammation and vascular endothelial dysfunction we are searching improve level of NO ( in all types cardiac patients) so I think for such category of patients may be hbot could be used even before any COVID19 infection ?.. ( may be than if their capacity to produce nitric oxide (NO)will be normalise or almost) we will see much more less cardiac person with bad Covid 19 outcome ????

This study as well…. 

https://www.researchgate.net/publication/321256684_Effects_of_hyperbaric_oxygen_on_vascular_endothelial_function_in_patients_with_slow_coronary_flow

why Professor Raoult’s protocol is not tested stricto sensu in the Discovery trial?

I would like to know why Professor Raoult’s protocol is not tested stricto sensu in the Discovery trial?

As a reminder, the Raoult protocol is: hydroxychloroquine (200 mg x 3 per day for 10 days) + Azithromycin (500 mg on the 1st day then 250 mg per day for 5 more days)

the Raoult protocol made so much noise that the state was obliged to include it in its European discovery trial ….. but not its protocol

Study: https://www.sciencedirect.com/science/article/pii/S0924857920300996

Didier Raoult (born March 13, 1952 in Dakar, Senegal) [1] is a French physician and microbiologist. He holds M.D. and Ph.D. degrees and specializes in infectious diseases. In 1984, Raoult created the Rickettsia Unit at Aix-Marseille University (AMU). He also teaches infectious diseases in the Faculty of Medicine of Aix-Marseille University, and since 1982 has supervised many M.D. and Ph.D. degrees. [2]

https://en.wikipedia.org/wiki/Didier_Raoult

It is the only molecule which is no longer under patent of the protocol so they do not want it, but since it made a fuss, to calm everyone, they include chloroquine in the European test but not following the right protocol like that it will not work and they can say: well here you see we listened to you

Like that everyone happy.

They could not think that like you we are a lot because we are informed to have understood that the purpose of including chloroquine in the test is to discredit it.

It is exactly the same for the chloroquine restriction decree which authorizes its use for severe cases (by our French government) where the Raoult protocol highlights the low efficacy of chloroquine in severe cases!

there are over 30 clinical trials registered on clinicaltrialsdotgov right now for hydroxychloroquine. not just treating covid-19 infected but prophylactic treatment of health care professionals treating covid-19 patients. so doesn’t mean they are ethics approved. but wow.

Meanwhile, 3 big names in health-management in France support Raoult …

Dominique Maraninchi, Fabien Calvo and Jean-Luc Harousseau, former directors and presidents of the ANSM, the HAS and the INCA.

https://www.lefigaro.fr/vox/societe/chloroquine-l-appel-de-trois-grands-noms-de-la-sante-en-faveur-des-preconisations-du-pr-raoult-20200405

But they are saying Hydroxychloroquine-COVID-19 study did not meet publishing society’s “expected standard”:

https://retractionwatch.com/2020/04/06/hydroxychlorine-covid-19-study-did-not-meet-publishing-societys-expected-standard/